Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Yingxiao Shi, Zoltan Maliga, Tuulia Vallius, Shishir Mani Pant, Roxanne J. Pelletier, Brigette Kobs, Priyanka Solanky, Yiwen He, Eliezer M. Van Allen, Sandro Santagata, Patrick Alexander Ott, Christine Guo Lian, Elizabeth Iannotti Buchbinder, David Liu, Peter Karl Sorger
This study shows that immunogenic tumor mass dormancy, not cell-level quiescence, persists in residual melanoma lesions after immunotherapy, with active tumor cells and immune interactions.
bioRxiv · Jun 27, 2026 · PreprintCancer Biology